Santos Heitor O, Cerqueira Henrique S, Tinsley Grant M
School of Medicine, Federal University of Uberlandia (UFU), Uberlandia 38408-100, Brazil.
School of Medicine, University of São Paulo (USP), Ribeirão Preto 14049-900, Brazil.
Metabolites. 2022 Nov 20;12(11):1146. doi: 10.3390/metabo12111146.
Myostatin, a secreted growth factor belonging to the transforming growth factor β (TGF-β) family, performs a role in hindering muscle growth by inhibiting protein kinase B (Akt) phosphorylation and the associated activation of hypertrophy pathways (e.g., IGF-1/PI3K/Akt/mTOR pathway). In addition to pharmacological agents, some supplements and nutraceutical agents have demonstrated modulatory effects on myostatin levels; however, the clinical magnitude must be appraised with skepticism before translating the mechanistic effects into muscle hypertrophy outcomes. Here, we review the effects of dietary supplements, nutraceutical agents, and physical exercise on myostatin levels, addressing the promise and pitfalls of relevant randomized clinical trials (RCTs) to draw clinical conclusions. RCTs involving both clinical and sports populations were considered, along with wasting muscle disorders (e.g., sarcopenia) and resistance training-induced muscle hypertrophy, irrespective of disease status. Animal models were considered only to expand the mechanisms of action, and observational data were consulted to elucidate potential cutoff values. Collectively, the effects of dietary supplements, nutraceutical agents, and physical exercise on myostatin mRNA expression in skeletal muscle and serum myostatin levels are not uniform, and there may be reductions, increases, or neutral effects. Large amounts of research using resistance protocols shows that supplements or functional foods do not clearly outperform placebo for modulating myostatin levels. Thus, despite some biological hope in using supplements or certain functional foods to decrease myostatin levels, caution must be exercised not to propagate the hope of the food supplement market, select health professionals, and laypeople.
肌生成抑制素是一种属于转化生长因子β(TGF-β)家族的分泌型生长因子,它通过抑制蛋白激酶B(Akt)磷酸化以及相关的肥大途径激活(如IGF-1/PI3K/Akt/mTOR途径)来阻碍肌肉生长。除了药物制剂外,一些补充剂和营养保健品已显示出对肌生成抑制素水平的调节作用;然而,在将其作用机制转化为肌肉肥大结果之前,必须谨慎评估其临床效果。在此,我们综述了膳食补充剂、营养保健品和体育锻炼对肌生成抑制素水平的影响,探讨相关随机临床试验(RCT)得出临床结论的前景与陷阱。考虑了涉及临床和运动人群的RCT,以及肌肉萎缩性疾病(如肌肉减少症)和抗阻训练诱导的肌肉肥大,无论疾病状态如何。仅考虑动物模型以扩展作用机制,并参考观察性数据以阐明潜在的临界值。总体而言,膳食补充剂、营养保健品和体育锻炼对骨骼肌中肌生成抑制素mRNA表达和血清肌生成抑制素水平的影响并不一致,可能会有降低、升高或中性作用。大量使用抗阻方案的研究表明,补充剂或功能性食品在调节肌生成抑制素水平方面并不明显优于安慰剂。因此,尽管在使用补充剂或某些功能性食品降低肌生成抑制素水平方面存在一些生物学上的希望,但必须谨慎行事,以免助长食品补充剂市场、健康专业人员和普通民众的期望。